Efficacy and safety using optimization MMF of dosing by monitoring

Efficacy and safety using optimization MMF of dosing by monitoring - Efficacy and safety using optimization MMF of dosing by monitoring

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021582

Enrollment

Registered

2016-03-23

Start date

2011-07-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal-transplant recipients and liver-transplant recipients and refractry GVHD

Interventions

Mycophenolate Mofetil administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who receive mycophenolate mofetil.

Exclusion criteria

Exclusion criteria: The patients who do not obtain consent for this study.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic analysis of MPAG and MPA	—

Secondary

Measure	Time frame
Efficacy and safety	—

Countries

Japan

Contacts

Public ContactHideaki Maeba

Kanazawa University Pediatrics

pedialib@med.kanazawa-u.ac.jp076-265-2313

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026